JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

MannKind Corp

Затворен

СекторЗдравеопазване

3.51 2.93

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.51

Максимум

3.54

Ключови измерители

By Trading Economics

Приходи

5.7M

13M

Продажби

1.6M

78M

P/E

Средно за сектора

39.2

34.393

Марж на печалбата

16.793

Служители

403

EBITDA

8.3M

27M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+163.92% upside

Дивиденти

By Dow Jones

Следващи печалби

6.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-316M

1.2B

Предишно отваряне

0.58

Предишно затваряне

3.51

Настроения в новините

By Acuity

14%

86%

21 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

MannKind Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.08.2025 г., 21:43 ч. UTC

Печалби

Constellation Software 2Q Revenue Rises, Profit Shrinks

8.08.2025 г., 16:39 ч. UTC

Придобивния, сливания и поглъщания

Vinci Faces Reduced Earnout Payments to ACS for Cobra IS Deal

8.08.2025 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

The Paramount Merger Was a Bad Deal for Old Shareholders. Buying the Stock Is a Good Bet for New Ones. -- Barrons.com

8.08.2025 г., 21:31 ч. UTC

Пазарно говорене
Печалби

Cautious Long-Term Outlook For Natural Diamond Prices -- Market Talk

8.08.2025 г., 21:00 ч. UTC

Печалби

Constellation Software 2Q Rev $2.84B >CSU.T

8.08.2025 г., 21:00 ч. UTC

Печалби

Constellation Software 2Q Net $56M >CSU.T

8.08.2025 г., 21:00 ч. UTC

Печалби

Constellation Software 2Q EPS $2.66 >CSU.T

8.08.2025 г., 20:55 ч. UTC

Пазарно говорене

Ahead of Cisco's Earnings, Investors Should Expect Conservatism -- Market Talk

8.08.2025 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

8.08.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.08.2025 г., 20:35 ч. UTC

Пазарно говорене

Mexico's Industrial Production Seen Higher in June -- Market Talk

8.08.2025 г., 20:28 ч. UTC

Печалби

MP Materials Stock Soars Even Higher on Earnings. The Future Looks Bright, Too. -- Barrons.com

8.08.2025 г., 20:28 ч. UTC

Печалби

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

8.08.2025 г., 20:20 ч. UTC

Придобивния, сливания и поглъщания

Boeing's Spirit AeroSystems Deal Gets U.K. Approval. It's Part of the Turnaround. -- Barrons.com

8.08.2025 г., 20:08 ч. UTC

Печалби

Tredegar: Recent Decline in Orders, Which Is a Measure of Future Sales Volume, Is Due to Lower Demand for Aluminum Extrusions in U.S. and Customers Pausing Orders to Evaluate New Higher Tariff >TG

8.08.2025 г., 19:34 ч. UTC

Пазарно говорене

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8.08.2025 г., 19:15 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Under $3 -- Market Talk

8.08.2025 г., 19:13 ч. UTC

Пазарно говорене

Oil Futures End Volatile Week Lower -- Market Talk

8.08.2025 г., 18:21 ч. UTC

Пазарно говорене

Gold Gains for the Week as Tariffs Go Forward -- Market Talk

8.08.2025 г., 17:27 ч. UTC

Печалби

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Microchip, and More -- Barrons.com

8.08.2025 г., 17:09 ч. UTC

Печалби

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8.08.2025 г., 17:03 ч. UTC

Печалби

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8.08.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

8.08.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.08.2025 г., 15:53 ч. UTC

Придобивния, сливания и поглъщания

Vinci: New Provisions Will Have No Significant Impact on Vinci's Financial Statements

8.08.2025 г., 15:51 ч. UTC

Придобивния, сливания и поглъщания

Vinci, ACS Terminate Agreement Regarding Creation of Joint Venture in Renewable Energy

8.08.2025 г., 15:50 ч. UTC

Придобивния, сливания и поглъщания

Vinci to Pay EUR300M of That Sum to ACS Taking Into Account Payments Already Made

8.08.2025 г., 15:48 ч. UTC

Придобивния, сливания и поглъщания

Vinci, ACS Agreed to Fix Earn-Out Related to Cobra IS Developments in Renewable Energy at EUR380M Payable in Cash

8.08.2025 г., 15:47 ч. UTC

Придобивния, сливания и поглъщания

Vinci: Acquisition of Cobra IS Was Completed Dec. 31, 2021

8.08.2025 г., 15:46 ч. UTC

Придобивния, сливания и поглъщания

Vinci: Agreement Will Definitively Settle Certain Provisions Related to Acquisition of Cobra IS

Сравнение с други в отрасъла

Ценова промяна

MannKind Corp Прогноза

Ценова цел

By TipRanks

163.92% нагоре

12-месечна прогноза

Среден 9.29 USD  163.92%

Висок 12 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за MannKind Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

7

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

4.079 / 4.323Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

21 / 374 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.